Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation

We retrospectively reviewed 292 patients who received a second line of therapy post ASCT for their light chain amyloidosis. Most patients (40%) were treated with an alkylator + PI ± dex or PI ± dex followed by an alkylator + 2nd-gen IMiD ± dex or 2nd-gen IMiD ± dex (26%), an alkylator ± steroid or s...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Saleh, Abdullah S., Ebraheem, Mohammad S., Sidiqi, M. Hasib, Dispenzieri, Angela, Muchtar, Eli, Buadi, Francis K., Warsame, Rahma, Lacy, Martha Q., Dingli, David, Gonsalves, Wilson I., Kourelis, Taxiarchis V., Hogan, William J., Hayman, Suzanne R., Kapoor, Prashant, Kumar, Shaji K., Gertz, Morie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001695/
https://www.ncbi.nlm.nih.gov/pubmed/35410992
http://dx.doi.org/10.1038/s41408-022-00655-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001695/
https://www.ncbi.nlm.nih.gov/pubmed/35410992
http://dx.doi.org/10.1038/s41408-022-00655-z

Ejemplares similares